Corcept Therapeutics Inc
NASDAQ:CORT

Watchlist Manager
Corcept Therapeutics Inc Logo
Corcept Therapeutics Inc
NASDAQ:CORT
Watchlist
Price: 57.54 USD 2.9% Market Closed
Market Cap: 6B USD
Have any thoughts about
Corcept Therapeutics Inc?
Write Note

Corcept Therapeutics Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Corcept Therapeutics Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Corcept Therapeutics Inc
NASDAQ:CORT
Other Long-Term Assets
$141.5m
CAGR 3-Years
44%
CAGR 5-Years
18%
CAGR 10-Years
41%
Johnson & Johnson
NYSE:JNJ
Other Long-Term Assets
$19.8B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
9%
Bristol-Myers Squibb Co
NYSE:BMY
Other Long-Term Assets
$6.2B
CAGR 3-Years
38%
CAGR 5-Years
13%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Other Long-Term Assets
$18.6B
CAGR 3-Years
25%
CAGR 5-Years
27%
CAGR 10-Years
15%
Merck & Co Inc
NYSE:MRK
Other Long-Term Assets
$13.3B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Eli Lilly and Co
NYSE:LLY
Other Long-Term Assets
$12.5B
CAGR 3-Years
25%
CAGR 5-Years
22%
CAGR 10-Years
18%
No Stocks Found

Corcept Therapeutics Inc
Glance View

Market Cap
6B USD
Industry
Pharmaceuticals

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. The company is headquartered in Menlo Park, California and currently employs 238 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The company has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.

CORT Intrinsic Value
63.25 USD
Undervaluation 9%
Intrinsic Value
Price

See Also

What is Corcept Therapeutics Inc's Other Long-Term Assets?
Other Long-Term Assets
141.5m USD

Based on the financial report for Sep 30, 2024, Corcept Therapeutics Inc's Other Long-Term Assets amounts to 141.5m USD.

What is Corcept Therapeutics Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
41%

Over the last year, the Other Long-Term Assets growth was 38%. The average annual Other Long-Term Assets growth rates for Corcept Therapeutics Inc have been 44% over the past three years , 18% over the past five years , and 41% over the past ten years .

Back to Top